{
    "clinical_study": {
        "@rank": "16519", 
        "acronym": "PIP-SBT", 
        "arm_group": {
            "arm_group_label": "Piperacillin Sodium and Sulbactam Sodium", 
            "arm_group_type": "Experimental", 
            "description": "Drug:xintemie 1.5-3.0g,iv,bid 7-14 days\nserious infections 6.0-12.0g,iv,tid for 7-14 days"
        }, 
        "brief_summary": {
            "textblock": "In the proposed study, the investigators plan to evaluate the efficacy and safety of\n      Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for the treatment of respiratory\n      and urinary tract acute bacterial infection."
        }, 
        "brief_title": "Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Respiratory Tract Infections", 
            "Urinary Tract Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Respiratory Tract Infections", 
                "Urinary Tract Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "Piperacillin sodium and sulbactam sodium for injection (2:1)plays a therapeutic role by the\n      former inhibiting bacterial cell wall synthesis\uff0cthe latter making irreversible competitive\n      inhibition of \u03b2-lactamase.The antimicrobial effect of Piperacillin can be enhanced by the\n      two combined. The compound specifically aims to the mechanism of bacterial resistance,\n      extending the life of Piperacillin in the treatment-resistant pathogen infections."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. patients who qualify for moderate and severe acute respiratory or urinary tract\n             bacterial infection of acute bacterial infections need for systemic antibiotic\n             therapy.\n\n          2. Age>18 years old, Gender: both\n\n          3. Women of childbearing age were to be negative pregnancy test and agree to take\n             contraceptive measures during the trial;\n\n          4. patients were volunteers and signed informed consent form;\n\n          5. patients did not participate in other clinical trials.\n\n        Exclusion Criteria:\n\n          1. Patients were hypersusceptibility to the test drug or other penicillins ,\u03b2-lactamase\n             inhibitor\n\n          2. Pregnant and Lactating women\n\n          3. Patients have severe liver,kidney,cardiovascular,cerebrovascular,endocrine and\n             hematopoietic system of primary diseases and that of immunodeficiency,advanced cancer\n             or mental illness.\n\n          4. Patients who were complicated by other diseases and thought to affect efficacy\n             evaluations or poor compliance."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "2000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01760109", 
            "org_study_id": "2002HL0153"
        }, 
        "intervention": {
            "arm_group_label": "Piperacillin Sodium and Sulbactam Sodium", 
            "description": "1.5-3.0g,iv,bid 7-14 days serious infections 6.0-12.0g,iv,tid for 7-14 days", 
            "intervention_name": "Piperacillin Sodium and Sulbactam Sodium", 
            "intervention_type": "Drug", 
            "other_name": [
                "xin te mie", 
                "te mie jun", 
                "xin ke jun"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Piperacillin", 
                "Sulbactam"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Respiratory and urinary tract infections", 
            "Piperacillin Sodium and Sulbactam Sodium for Injection (2:1)", 
            "Phase IV"
        ], 
        "lastchanged_date": "December 30, 2012", 
        "location": {
            "contact": {
                "last_name": "Changqing Li, doctor", 
                "phone": "(023)88519201"
            }, 
            "facility": {
                "address": {
                    "city": "Chongqing", 
                    "country": "China", 
                    "zip": "400020"
                }, 
                "name": "Chongqing Red Cross hospital"
            }, 
            "investigator": {
                "last_name": "Changqing Li, doctor", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase IV Study on Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection", 
        "overall_contact": {
            "email": "wmrd@welman.com.cn", 
            "last_name": "Ting Wang, doctor", 
            "phone": "020-38868707"
        }, 
        "overall_contact_backup": {
            "email": "linrong@welman.com.cn", 
            "last_name": "Rong Lin, bachelor", 
            "phone": "020-38868707"
        }, 
        "overall_official": {
            "affiliation": "Chongqing Red Cross Hospital", 
            "last_name": "Changqing Li, doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "end of treatment of bacteriological efficacy(bactercial clearance) The fore-and-aft changes of clinical symptoms and signs after discontinuation of durgs", 
            "measure": "The rate of bacterial clearance", 
            "safety_issue": "No", 
            "time_frame": "two years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01760109"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "the incidence(%)of allergies, skin rashes, shock,death, etc.", 
            "measure": "Number of participants with Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "two years"
        }, 
        "source": "Xiangbei Welman Pharmaceutical Co., Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Xiangbei Welman Pharmaceutical Co., Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}